glp -1 drugs New GLP-1 Guidelines for Type 2 Diabetes in 2025 GLP-1 Drugs: 6 Things We've
Description
Front Endocrinol (Lausanne) 2021;12:645563
While preclinical studies support this hypothesis, robust clinical evidence remains limited
10.1016/S2213-8587(21)00203-5 [DOI] [PubMed] [Google Scholar] Scisciola L., Rizzo M
Table S1 Searching details of the meta-analysis
ADMA, Asymmetric dimethylarginine (an endogenous inhibitor of nitric oxide synthase, marker of endothelial dysfunction)
While the theoretical long-term benefits to health outcomes are welcomed, the short-term cost impact to health insurers must be considered
